The Sire Group Ltd Says Expect To Propose To Titan Pharmaceuticals Inc A Business Combination With KE Sdn. Bhd
The Sire Group Ltd Says Expect To Propose To Titan Pharmaceuticals Inc A Business Combination With KE Sdn. Bhd
Sire集团有限公司表示，预计将向泰坦制药公司提议与KE Sdn进行业务合并。Bhd
- SEC 13D/Amended Filing
-SEC 13D/修正申报
After giving effect to these changes in membership, as of April 2, 2024, four of the board's seven directors had been nominated by the reporting persons. The reporting persons expect to propose to the Issuer a business combination with KE Sdn. Bhd., a Malaysian company. Any such transaction would be subject to execution of definitive documents negotiated between the reporting persons and a committee of independent directors of the Issuer. This report does not constitute an offer of any securities for sale.
在这些成员变更生效后，截至2024年4月2日，董事会的七名董事中有四名已由申报人提名。申报人预计将向发行人提议与KE Sdn进行业务合并。Bhd.，一家马来西亚公司。任何此类交易都必须执行申报人与发行人独立董事委员会之间谈判的最终文件。本报告不构成任何待售证券的要约。